In this study, we examined whether infigratinib (BGJ 398), a potent and selective FGFR1-4 inhibitor can reverse the resistance of ABCB1-overexpressing cancer cells to the conventional chemotherapeutic agents PTX and doxorubicin (Dox), a topoisomerase II inhibitor. This evidence concerns the gene ABCB1 and cancer.